Creative Medical Technology Holdings, Inc. (CELZ) stock

CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30

$0.53−0.09 (-14.35%)

Close on Nov 13, 2026Market cap $3.48MP/E –Yield –

Creative Medical Technology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Creative Medical Technology's price to sales ratio was 488.5× on Jun 30, 2025, against 251.7× a year earlier.

Period	Period end	Value	Change (pts)
2025	Jun 30, 2025	488.5×	+209.2
2024	Dec 31, 2024	279.3×	+18.6
2023	Dec 29, 2023	260.7×	−128.7
2022	Dec 30, 2022	389.4×	–

Parsed from the XBRL in Creative Medical Technology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jun 12, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CELZ.

Advertisement
300 × 250

See a number that looks wrong?